A Multicenter, Open-label, Phase Ⅲ Study to Evaluate the Efficacy and Safety of Amphotericin B Liposome for Injection in Patients With Persistent Febrile Neutropenia

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.0 sites93 target enrollmentDecember 15, 2021

ConditionsNeutropenia and Fever

InterventionsAmphotericin B liposomes

DrugsAmphotericin B liposomes

Overview

Phase: Phase 3
Intervention: Amphotericin B liposomes
Conditions: Neutropenia and Fever
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Enrollment: 93
Primary Endpoint: Overall success rate
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

This is a multicenter, open-label, single-arm, phase III study to evaluate the safety and efficacy of Amphotericin B liposomes in patients with persistent neutropenia and fever.

Detailed Description

This is a multicenter, open-label, single-arm, phase III study to evaluate the safety and efficacy of Amphotericin B liposomes in patients with persistent neutropenia and fever. About 93 patients will be recruited in this study. The patients will receive Amphotericin B liposomes intravenous infusion at a dose of 3 mg/kg over 2 hours once daily (qd) for a maximum of 12 weeks.

Registry

clinicaltrials.gov

Start Date

December 15, 2021

End Date

January 15, 2023

Last Updated

4 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Aged 18 \~ 75 years (inclusive), no gender limitation.
•Patients with neutrophilic deficiency after solid tumor chemotherapy, hematological tumor chemotherapy, hematopoietic stem cell transplantation, etc. (absolute neutrophil count (ANC) in peripheral blood \<500 /mm\^3 (0.5×10\^9 /L) for at least 72 hours at screening).
•Persistent or recurrent fever (oral temperature ≥38℃ or axillary temperature ≥37.7℃ within 24 hours prior to randomization) after at least 72 hours on broad-spectrum antibiotics, and considering fever to be associated with suspected fungal infection.
•Female patients must meet one of the following conditions:
•Menopausal patients, menopause at least 1 year;
•Patients of childbearing age: Negative for blood/urine pregnancy test before enrollment; agree to take a guaranteed, effective contraception during the study and within 4 weeks after the study.
•Male patients and their partners must use effective contraception throughout the study period and up to 4 weeks after leaving the study.
•Patients fully understand and voluntarily participate in this study and sign informed consent.

Exclusion Criteria

•History of allergy to liposomes or amphotericin B.
•Received systemic treatment of amphotericin B or amphotericin B-containing formulation within 10 days prior to enrollment.
•Liposome used within 1 month before the signing informed consent.
•Confirmed or clinically diagnosed invasive fungal infection or known uncontrolled bacteremia or sepsis at screening.
•Eastern Cooperative Oncology Group (ECOG) performance status ≥3;
•Abnormal liver function, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≥5 × the upper limit of normal (ULN), or ALT/AST ≥3 × ULN with total bilirubin ≥1.5 × ULN, or total bilirubin ≥3 × ULN.
•Serum creatinine \> 2 × ULN.
•Serum potassium concentration ≤3.0 mmol/L prior to the first administration, or serum potassium concentration ≤the lower limit of normal value (LLN) in patients undergoing digitalization.
•12-lead ECG presenting II or III degree atrioventricular block, long QT syndrome or corrected QT interval\>480 ms in the absence of a pacemaker.
•Cardiac function grade III/IV (NYHA).

Arms & Interventions

Amphotericin B liposomes

Patients with suspected fungal neutropenia and fever will receive amphotericin B liposome 3 mg/kg intravenously. Treatment will be continued until the ANC≥500 /mm\^3 (0.5×10\^9 /L) for more than 72 hrs in terms of patients without evidence of baseline fungal infection and breakthrough fungal infection; or treatment will be continued according to investigator's judgement with a duration ranging from 14 days to 12 weeks in terms of patients with evidence of baseline fungal infection and breakthrough fungal infection.

Intervention: Amphotericin B liposomes

Outcomes

Primary Outcomes

Overall success rate

Time Frame: From the initiation of the third dose to 7 days after the last dose

A successful outcome is defined as fulfilling all components of a prespecified 5-part composite endpoint.

Secondary Outcomes

Percentage of patients without discontinuation of study drug due to side effects or lack of efficacy during the treatment period(From the initiation of the third dose to 7 days after the last dose)
Percentage of patients with complete or partial remission of confirmed or clinically diagnosed IFD (baseline fungal infection) at the end of treatment(From the initiation of the third dose to 7 days after the last dose)
Percentage of patients without new fungal infections from the initiation of the first dose to 7 days after the last dose(From the initiation of the third dose to 7 days after the last dose)
Percentage of patients survived from the initiation of the first dose to 7 days after the last dose(From the initiation of the third dose to 7 days after the last dose)
Adverse events(From the screening period to 14 days after the last dose)
Percentage of patients experienced fever reduction during neutropenia after initiation of treatment(From the initiation of the third dose to 7 days after the last dose)
Pharmacokinetic profile of amphotericin B(Pre-dose and multiple timepoints up to 4 hours of the last dosePharmacokinetic profile of amphotericin B, Such as "Area under the plasma concentration versus time curve (AUC)")